Aim: To determine the overall survival rate of patients with Ewing sarcoma after pre and post radiation treatment. Material and Methods: The research had a cohort of 100 individuals, all of whom were diagnosed with Ewing sarcoma. A total of 50 patients had pre-radiation treatment, while another 50 individuals received post-radiation treatment. The research protocol underwent a thorough examination and received official approval from the institutional review board. Due to the study's retrospective nature, patient permission was not required. However, all data were anonymised to ensure the anonymity of the patients. Patients were chosen based on precise inclusion criteria: they must have a confirmed diagnosis of Ewing sarcoma by histological examination, have had both pre- and post-radiation therapy as part of their treatment plan, and have complete medical records that may be reviewed. Results: The average period of follow-up was 37.34 months (standard deviation ± 5.47) for the group that received pre-radiation treatment, and 38.12 months (standard deviation ± 5.76) for the group that received post-radiation therapy. The average period of follow-up was 37.73 months, with a standard deviation of 5.62. Among the patients who had pre-radiation treatment, 58% were still living, while 42% had passed away. Among the individuals who had radiation treatment, 62% were still living, while 38% had passed away. The overall survival rate for all patients was 60%, whereas 40% of the patients passed away. The pre-radiation treatment group had a median survival time of 43 months, whereas the post-radiation therapy group had a median survival time of 46 months. The median survival time for the whole population was 44.5 months. The pre-radiation treatment group had a median survival time of 43 months, whereas the post-radiation therapy group had a median survival time of 46 months. The 1-year survival rate was 92% in the pre-radiation treatment group and 94% in the post-radiation therapy group. The pre-radiation treatment group had a 3-year survival rate of 66%, whereas the post-radiation therapy group had a 3-year survival rate of 70%. The 5-year survival rate was 60% for the group who received radiation therapy before to treatment, and 64% for the group that received radiation therapy after treatment. Conclusion: Our analysis determined that both pre- and post-radiation treatment sequences are feasible, with a modest benefit in terms of survival for post-radiation therapy. The recognition of tumor size as a key prognostic determinant emphasizes the need of promptly detecting and treating bigger tumors with a strong approach.